Ginkgo Bioworks Holdings Inc (DNA) kicked off at the price of $1.51: Venture capitalists have an exciting new opportunity

Ginkgo Bioworks Holdings Inc (NYSE: DNA) kicked off on Monday, up 7.09% from the previous trading day, before settling in for the closing price of $1.41. Over the past 52 weeks, DNA has traded in a range of $1.12-$2.55.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 180.81%. While this was happening, its average annual earnings per share was recorded 64.80%. With a float of $1.32 billion, this company’s outstanding shares have now reached $1.34 billion.

Ginkgo Bioworks Holdings Inc (DNA) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.82%, while institutional ownership is 58.83%. The most recent insider transaction that took place on Feb 02, was worth 47,799. In this transaction an insider of this company sold 39,569 shares at a rate of $1.21, taking the stock ownership to the 761,737 shares. Before that another transaction happened on Jan 04, when Company’s insider sold 100,000 for $1.55, making the entire transaction worth $155,500. This insider now owns 3,894,680 shares in total.

Ginkgo Bioworks Holdings Inc (DNA) Recent Fiscal highlights

In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.16 earnings per share (EPS), lower than consensus estimate (set at -$0.09) by -$0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 64.80% per share during the next fiscal year.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators

Take a look at Ginkgo Bioworks Holdings Inc’s (DNA) current performance indicators. Last quarter, stock had a quick ratio of 6.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.58.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.30 in one year’s time.

Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)

Looking closely at Ginkgo Bioworks Holdings Inc (NYSE: DNA), its last 5-days average volume was 19.67 million, which is a drop from its year-to-date volume of 21.85 million. As of the previous 9 days, the stock’s Stochastic %D was 85.15%. Additionally, its Average True Range was 0.10.

During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 41.05%, which indicates a significant decrease from 94.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.49% in the past 14 days, which was lower than the 82.89% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.4234, while its 200-day Moving Average is $1.6559. However, in the short run, Ginkgo Bioworks Holdings Inc’s stock first resistance to watch stands at $1.5617. Second resistance stands at $1.6133. The third major resistance level sits at $1.6967. If the price goes on to break the first support level at $1.4267, it is likely to go to the next support level at $1.3433. Now, if the price goes above the second support level, the third support stands at $1.2917.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats

The company with the Market Capitalisation of 3.02 billion has total of 2,118,437K Shares Outstanding. Its annual sales at the moment are 477,710 K in contrast with the sum of -2,105 M annual income. Company’s last quarter sales were recorded 55,430 K and last quarter income was -302,890 K.